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Abstract: BACKGROUND Unresectable cholangiocarcinoma has a poor prognosis and treatment options
are limited. Combined systemic and intrahepatic chemotherapy may improve local control and enable
downsizing. The aim of this study was to determine the maximum tolerated dose (MTD) of intravenous
gemcitabine combined with intravenous cisplatin and hepatic arterial infusion (HAI) with floxuridine
(FUDR) in patients with unresectable intrahepatic or hilar cholangiocarcinoma. METHODS Twelve
patients were treated within a 3 + 3 dose escalation algorithm with 600, 800, or 1,000 mg/m2 gemcitabine
and predefined doses of cisplatin 25 mg/m2 on days 1 and 8, q21, for 4 cycles, and FUDR 0.2 mg/kg
on days 1-14 as continuous HAI, q28, for 3 cycles. Safety and toxicity as well as resectability rates after
3 months and preliminary survival data are reported. RESULTS The determined MTD for gemcitabine
was 800 mg/m2. Dose limiting toxicities were neutropenic fever and biliary tract infections. In total,
27% of the patients showed partial remission and 73% stable disease. Although none of the patients
achieved resectability after 3 months, the 3-year overall survival rate was 33%, median overall survival 23.9
months (range 1-49), and median progression-free survival 10.1 months (range 2-40). CONCLUSIONS
Intravenous gemcitabine/cisplatin plus HAI-FUDR is feasible and appears effective for disease control.
Larger prospective studies evaluating this triplet combination are warranted.
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Abstract
Background: Unresectable cholangiocarcinoma has a poor 
prognosis and treatment options are limited. Combined sys-
temic and intrahepatic chemotherapy may improve local 
control and enable downsizing. The aim of this study was to 
determine the maximum tolerated dose (MTD) of intrave-
nous gemcitabine combined with intravenous cisplatin and 
hepatic arterial infusion (HAI) with floxuridine (FUDR) in pa-
tients with unresectable intrahepatic or hilar cholangiocar-
cinoma. Methods: Twelve patients were treated within a 3 + 
3 dose escalation algorithm with 600, 800, or 1,000 mg/m2 
gemcitabine and predefined doses of cisplatin 25 mg/m2 on 
days 1 and 8, q21, for 4 cycles, and FUDR 0.2 mg/kg on days 
1–14 as continuous HAI, q28, for 3 cycles. Safety and toxicity 
as well as resectability rates after 3 months and preliminary 
survival data are reported. Results: The determined MTD for 
gemcitabine was 800 mg/m2. Dose limiting toxicities were 
neutropenic fever and biliary tract infections. In total, 27% of 
the patients showed partial remission and 73% stable dis-
ease. Although none of the patients achieved resectability 
after 3 months, the 3-year overall survival rate was 33%, me-
dian overall survival 23.9 months (range 1–49), and median 
progression-free survival 10.1 months (range 2–40). Conclu-
sions: Intravenous gemcitabine/cisplatin plus HAI-FUDR is 
feasible and appears effective for disease control. Larger pro-
spective studies evaluating this triplet combination are war-
ranted. © 2021 The Author(s)
Published by S. Karger AG, Basel
Introduction
Cholangiocarcinoma (CCA) arises from the biliary epi-
thelium of intra- and extrahepatic bile ducts. The inci-
dence of intrahepatic CCA has increased markedly in the 
ClinicalTrials.gov Identifier: NCT01692704, registered on September 
25, 2012.
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last decades, while the incidence of extrahepatic CCA has 
increased only modestly [1]. CCA is associated with a poor 
prognosis, and mortality rates also seem to have increased 
during the last decades, according to registry data [2]. Sur-
gery offers the only chance for long-term survival for CCA 
patients, but it is curative only in the minority of all cases, 
with a 9–18% 5-year survival rate for hilar/intrahepatic 
CCA and 20–30% for distal lesions [3]. Only a few selected 
patients with localized hilar CCA qualify for a multimodal-
ity treatment, eventually followed by a liver transplanta-
tion. This approach may lead to 5-year survival rates of up 
to 80%, according to the Mayo Clinic experience [4].
However, the disease is often locally too advanced to 
allow for complete resection. Therefore, strategies for 
downsizing intrahepatic or hilar CCA confined to the liv-
er without extrahepatic spread are needed. The ABC-02 
phase III trial established the current standard of system-
ic chemotherapy in advanced biliary tract cancer, but it 
showed an only modest survival benefit for patients treat-
ed with gemcitabine-cisplatin compared to those treated 
with gemcitabine monotherapy (11.7 vs. 8.1 months) [5]. 
Konstantinidis et al. [6] presented promising data with 
hepatic arterial infusion (HAI) chemotherapy by using 
floxuridine (FUDR) in patients with unresectable CCA in 
a retrospective analysis. Objective response rates of up to 
59% and a prolonged overall survival (OS) with combined 
HAI and systemic chemotherapy compared to systemic 
treatment alone have been observed retrospectively (30.8 
vs. 18.4 months; p < 0.001) [6, 7]. Recently, the combina-
tion of HAI with FUDR plus systemic gemcitabine and 
oxaliplatin was shown to be well tolerated and active in a 
phase II trial [8].
Selective HAI to the liver has been available for more 
than four decades, and is currently under evaluation for 
different tumor entities and clinical settings [6, 9–14]. 
Whilst blood supply to the liver parenchyma arises from 
both the hepatic artery and the portal vein, most hepatic 
tumors, including CCA, are almost exclusively perfused 
by the hepatic artery. FUDR is an active metabolite of 
5-fluorouracil and has a 90% extraction rate within the 
liver on the first pass. Local infusion of FUDR into the 
hepatic artery will therefore expose the tumor to high 
drug concentrations with minimal systemic exposure [5]. 
The safety of FUDR and the benefit of HAI have been 
demonstrated predominantly in patients with colorectal 
liver metastases, either as a downsizing strategy or as ad-
juvant treatment after resection of colorectal metastases 
[14–16].
Preclinical data indicate synergistic activity of FUDR 
and gemcitabine in colon cancer cells. Application of both 
drugs led to more than additive growth inhibition and in-
terference with colony formation in HT-29 colon cancer 
cells [17]. No preclinical data exist on the application of 
all three drugs combined. In light of these sparse data, we 
decided to combine these two treatment modalities – HAI 
with FUDR and systemic chemotherapy with cisplatin 
and gemcitabine – to develop a new downsizing strategy 
exclusively for patients with locally advanced, unresect-
able intrahepatic or hilar CCA without distant metastases 
who are not candidates for liver transplantation. Gem-
citabine was the preferred systemic combination partner 
with FUDR in the retrospective study of Konstantinidis et 
al. [6] mentioned above, but data on drug dosing and 
modifications were not reported. Cisplatin and FUDR 
have been studied in the past as combined HAI, and this 
double combination seems to be feasible. Taken together, 
both gemcitabine and cisplatin have been combined each 
with FUDR without excessive toxicities reported, but safe-
ty data on the administration of all three drugs together 
are lacking. Since FUDR has been shown to be safe and 
efficacious, we kept the established HAI dose and chose 
gemcitabine for dose escalation because of the rather high 
standard dose of 1,000 mg/m2 usually administered intra-
venously compared to cisplatin. This clinical study is 
therefore a “first-in-human” treatment approach.
Subjects and Methods
Patients
In this open-label, prospective, nonrandomized, single-arm 
dose escalation study (ClinicalTrials.gov Identifier: NCT01692704), 
12 patients with unresectable CCA were included between June 
2012 and January 2016 at the University Hospital Zurich, Switzer-
land. The trial design is depicted in Figure 1.
The main inclusion criteria were: (1) having nonresectable, his-
tologically or cytologically proven cholangiocellular adenocarcino-
ma including gallbladder cancer; (2) being no candidate for liver 
transplantation; (3) having no extrahepatic tumor spread, as evalu-
ated by PET-CT (positron emission tomography combined with 
computed tomography) of the chest and the abdomen/pelvis with 
the exception of limited indetermined and potentially resectable 
small lung nodules or hilar lymph node involvement; and (4) having 
adequate liver function and kidney function test results, including 
bilirubin <2× the upper limit of normal (ULN), aspartate amino-
transferase <5× ULN, alanine aminotransferase <5× ULN, and alka-
line phosphatase <5× ULN. The main exclusion criteria were: (1) an 
anatomic variant in the arteriogram, which prevents selective deliv-
ery of chemotherapy to the liver, and (2) a life expectancy <3 months.
The purpose of this study was to evaluate the safety and toxic-
ity of this combined regional and systemic treatment over a treat-
ment period of 3 months. Patients were allowed to continue this 
triplet treatment after the end of the 3-month study period if it was 
tolerated and efficacious. The primary objective was the definition 
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of the maximum tolerated dose (MTD) of intravenous gemcitabine 
in combination with intravenous cisplatin and intra-arterial 
FUDR. Secondary objectives were: (1) the response rate, using Re-
sponse Evaluation Criteria in Solid Tumors (RECIST 1.1) after 3 
months of chemotherapy; (2) the rate of conversion to resectabil-
ity; (3) surgical complications; (4) the toxicity of the chemotherapy 
according to the Common Terminology Criteria for Adverse 
Events (CTCAE) v4.03 reporting system; (5) progression-free sur-
vival (PFS); and (6) OS. Surgical complications were ranked ac-
cording to the Clavien-Dindo classification with calculation of the 
Comprehensive Complication Index (CCI) [18, 19]. This system 
ranks complications by severity according to their therapeutic 
consequences. Thus, grade I and II complications are events re-
quiring only bedside procedures or pharmacologic treatments, 
whereas grade III complications require surgical, radiological, or 
endoscopic treatment. Grade IV complications are life-threaten-
ing complications, and grade V complications correspond to 
death. The CCI is based on the complication grading of the Cla-
vien-Dindo classification and implements every occurred compli-
cation after an intervention. The overall morbidity is reflected on 
a scale from 0 (“no complication”) to 100 (“death”).
Administration Technique for HAI-FUDR
For the intra-arterial administration of FUDR, we used a to-
tally implantable pump device (CODMAN 3000 implantable infu-
sion pump; Codman & Shurtleff Inc.) with a refillable reservoir. 
During a laparotomy, the hepatoduodenal ligament was ap-
proached and the gastroduodenal artery (GDA) dissected and en-
circled. The pump catheter was inserted into the GDA at its junc-
tion with the common hepatic artery. A separate, transverse skin 
incision was made in the right lower abdominal quadrant, and a 
subcutaneous pocket was tailored. The pump was placed into this 
pocket and fixed to the fascia to avoid dislocation of the device. 
Appropriate placement of the catheter in the GDA was confirmed 
during laparotomy by infusion of fluorescein into the pump and 
evaluating the liver parenchyma with a hand-held Woods lamp. 
Finally, the gallbladder was resected and the abdomen was closed.
Regional HAI-FUDR Chemotherapy
The patients received FUDR 0.2 mg/kg/day for 14 days in com-
bination with a total of 20 mg dexamethasone and a total of 50,000 
units of heparin diluted in NaCl 0.9% to a total volume of 30 mL 
into the pump reservoir, repeated at day 29, for a total of 3 cycles. 
The pump reservoir was filled with 30 mL saline and 50,000 units 
of heparin for days 15–28 of each cycle to maintain a continuous 
efflux and thus avoid catheter occlusion.
Systemic Chemotherapy
Cisplatin 25 mg/m2 was administered as intravenous infusion 
at days 1 and 8, repeated on day 22, for a total of 4 cycles. Gem-
citabine was given according to the dose level the patient was treat-
ed with, i.e., 600 mg/m2 (dose level 1), 800 mg/m2 (dose level 2), or 
1,000 mg/m2 (dose level 3) as intravenous infusion at days 1 and 8, 
repeated on day 22, for a total of 4 cycles.
Dose Escalation
A traditional dose level escalation set-up was used to define the 
MTD for gemcitabine following a 3 + 3 algorithm. The first cohort 
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Fig. 1. Trial overview. FUDR, floxuridine; Dex, dexamethasone.




of 3 patients received gemcitabine at dose level 1 (600 mg/m2) in 
combination with cisplatin and FUDR. Once all 3 patients at a 
given dose level had received at least 2 applications of systemic 
chemotherapy and 1 out of these 3 patients had received 4 applica-
tions of systemic chemotherapy and if no dose limiting toxicity 
(DLT) occurred, the next 3 patients were included at the next-
higher dose level. If 1 out of a cohort of 3 patients experienced a 
DLT, 3 additional patients were recruited at the same dose level. If 
no further DLT were experienced in this cohort of 6 patients, the 
dose was escalated to the next higher level for subsequent patients. 
If a second DLT was observed at the same dose level, all further 
patients would have been deescalated to the previous dose level.
Maximum Tolerated Dose
The MTD of gemcitabine in combination with fixed doses of 
cisplatin and FUDR was defined as one dose level below the dose 
level that caused DLTs in more or equal than one-third of patients 
(2 or more in a cohort of 6 patients), as described above (3 + 3 al-
gorithm).
Dose Limiting Toxicity
A DLT was defined as an adverse event (AE) or laboratory ab-
normality that fulfilled one of the following criteria during the first 
4 applications of systemic treatment: (1) grade 4 neutropenia last-
ing ≥7 days or febrile neutropenia; (2) grade 4 thrombocytopenia; 
(3) grade 3 or 4 gastrointestinal symptoms (diarrhea, vomiting, or 
mucositis) which were not reduced to grade 1 within 7 days of ap-
propriate supportive care; (4) grade 3/4 skin toxicity, for example, 
rash or hand-foot syndrome; (5) grade 3/4 pulmonary toxicity, for 
example, dyspnea, edema, or alveolitis, which did not resolve to 
grade 1 within 3 days after gemcitabine cessation; (6) grade 3/4 
elevation of liver transaminases despite discontinuation of HAI-
FUDR; (7) any grade 3/4 toxicity which was considered to be dose 
limiting after discussion between the investigators and the spon-
sor.
Statistical Methods
All statistical analyses were performed using the SPSS software 
package, version 20.0 (Chicago, IL, USA). PFS and OS analyses 
were performed using the Kaplan-Meier method. PFS was defined 
as the time from start of chemotherapy to radiologically confirmed 
progression or death from any cause, whichever occurred first. OS 
was defined as the time from start of chemotherapy until death 
from any cause. Patients alive at the time of evaluation were cen-
sored at the last follow-up (the cut-off date was April 30, 2018).
Results
Patient Characteristics
In total, 12 patients ≥18 years were enrolled in the 
study. The majority of the patients had intrahepatic CCA 
(75%), and hilar CCA or gallbladder cancer was present 
in 17 and 8% of the patients, respectively. Poor risk fac-
tors, such as poorly differentiated tumors and lymph 
node involvement, were documented in 42 and 33%, re-
spectively. The majority of the patients (83%) were treat-
ment naïve. Detailed patient characteristics at baseline 
are listed in Table 1.
Dose Escalation and Toxicity Including DLT and MDT
The initial dose for cohort 1 (n = 3) was gemcitabine 
600 mg/m2 on days 1 and 8 intravenously every 3 weeks. 
Cisplatin 25 mg/m2 on days 1 and 8 intravenously every 
3 weeks and FUDR 0.2 mg/kg body weight on days 1–14 
as continuous hepatic intra-arterial infusion every 4 
weeks were administered per protocol. No DLTs and no 
grade 4 toxicities occurred at this dose level.
Dose escalation of gemcitabine to 800 mg/m2 on days 
1 and 8 intravenously every 3 weeks was performed as 
scheduled in dose level 2 (n = 3). Cisplatin and FUDR 
were administered at their predefined doses as before. At 
this dose level as well, no DLTs and no grade 4 toxicities 
occurred.
At dose level 3 (n = 3), gemcitabine was escalated to 
1,000 mg/m2 on days 1 and 8 intravenously every 3 weeks, 
while the doses of cisplatin and FUDR remained un-
changed. At this level, we observed grade 4 toxicities in 2 
out of 3 patients (cholangiosepsis, non-gastrointestinal-
related sepsis, and lymphopenia), with 1 DLT due to re-
current cholangiosepsis despite discontinuation of 
Table 1. Patients’ characteristics at baseline (n = 12)



















Previous chemotherapy, n (%) 2 (17)
Liver function tests
ALT abnormal, n (range in U/L) (%) 7 (64–168) (58)
AST abnormal, n (range in U/L) (%) 9 (71–174) (75)
Bilirubin abnormal, n 
(range in umol/L) (%) 2 (3–41) (17)
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FUDR. One patient died 6 weeks after study enrollment 
due to a pulmonary embolism. This patient already had 
had an underlying thromboembolic disease before study 
enrollment due to a tumor-related thrombophilia. There-
fore, this grade 5 complication was not considered to be 
study drug related and not classified as a DLT.
Because of the aforementioned 1 DLT in cohort 3, we 
continued with an expansion cohort (n = 3) at the same 
dose of gemcitabine 1,000 mg/m2 on days 1 and 8 intra-
venously every 3 weeks and cisplatin and FUDR at their 
predefined doses. In the expansion cohort, we observed a 
grade 4 toxicity in 1 patient (neutropenic fever), which 
was classified as a second DLT per protocol.
In total, 2 DLTs occurred at dose level 3 with gem-
citabine 1,000 mg/m2. As a consequence, the MTD of 
gemcitabine was defined as 800 mg/m2 on days 1 and 8 
intravenously every 3 weeks, in combination with cispla-
tin 25 mg/m2 on days 1 and 8 intravenously every 3 weeks 
and FUDR 0.2 mg/kg body weight on days 1–14 as con-
tinuous intra-arterial hepatic infusion every 4 weeks.
AEs due to Study Drug Treatment
Grade 3/4 AEs were dose dependent and occurred 
mainly at dose level 3 with gemcitabine 1,000 mg/m2 (Ta-
bles 2, 3). The most frequent grade 3/4 AEs were anemia 
and neutro-, lympho- and thrombocytopenia, as well as 
liver function test elevation and fatigue.
In total, 67% of the patients completed the preplanned 
3 months of study treatment, and 33% (n = 4) of the pa-
tients did not: 1 patient developed recurrent biliary tract 
infections defined as DLTs and had to stop treatment, 1 
patient died 6 weeks after study enrollment following pul-
monary embolism due to an underlying thromboembolic 
disease, and 2 patients stopped for other reasons (1 due 
to psychiatric disorder and 1 due to non-study-drug-re-
lated biliary tract infection).
Two out of all 12 patients (17%) experienced a dose 
delay and dose reductions due to toxicity of systemic and 
intrahepatic chemotherapy. One patient in cohort 3 
(gemcitabine 1,000 mg/m2) had recurrent biliary tract in-
fections requiring treatment discontinuation; the other 










Anemia 9 (75) 5 (42) 4 (33) 0
Thrombopenia 9 (75) 7 (58) 2 (17) 0
Lymphopenia 7 (58) 4 (33) 2 (17) 1 (8)
Leukopenia 7 (58) 3 (25) 3 (25) 1 (8)
Neutropenia 6 (50) 2 (17) 4 (33) 0
Gastrointestinal and hepatic toxicity
Nausea 6 (50) 50 0 0
Anorexia 5 (42) 5 (42) 0 0
AST increase 4 (33) 2 (17) 2 (17) 0
AP increase 3 (25) 1 (8) 2 (17) 0
ALT increase 2 (17) 1 (8) 1 (8) 0
GGT increase 2 (17) 0 1 (8) 1 (8)
BLT infection 2 (17) 1 (8) 0 1 (8)*
Constipation 2 (17) 2 (17) 0 0
Diarrhea 2 (17) 2 (17) 0 0
Gastritis 2 (17) 2 (17) 0 0
Duodenal ulceration 1 (8) 1 (8) 0 0
Others
Fatigue 8 (67) 4 (33) 4 (33) 0
Infections other than BLT 4 (33) 1 (8) 2 (17) 1 (8)*
Hyponatremia 3 (25) 3 (25) 0 0
Tinnitus 2 (17) 2 (17) 0 0
Paresthesia 2 (17) 2 (17) 0 0
Fever 2 (17) 2 (17) 0 0
AP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BLT, biliary tract; 
GGT, γ-glutamyltransferase. * Dose limiting toxicity.




patient (expansion cohort, gemcitabine 1,000 mg/m2) 
had neutropenic fever due to an enterocolitis, which re-
quired a 25% dose reduction. Both were determined as 
DLTs.
In total, 16 serious AEs (SAEs) occurred during the 
study period; 10 SAEs were possibly or likely related to 
study drug treatment, and in all cases this was due to in-
fections requiring hospitalization (pneumonia, biliary 
tract infection, and enterocolitis). Other SAEs that were 
not related to study drug treatment were postoperative 
pain after pump insertion, biliary tract infection that had 
been present before initiation of study drug treatment, an 
episode of depression that was related to a psychiatric dis-
order that had been present before study enrollment, and 
a pulmonary embolism in a patient with underlying 
thromboembolic disease. One patient developed a volvu-
lus of the colon as described below.
No SAEs Were Considered as Suspected Unexpected 
Serious Adverse Reactions
All reported SAEs were within the expected range and 
were consistent with the known adverse reactions to the 
given therapy. There has been no change in the perceived 
risk of the trial treatment identified from the cumulative 
safety data. No new safety issues were identified.
Table 3. Grade 3/4 AEs





Hematological toxicity, n Gastrointestinal and 
hepatic toxicity, n




G3 G4 G3 G4 G3 G4
1 600 3 1 0 1 0 0 0 0 0
2 800 3 1 0 1 0 0 0 0 4
3 1,000 3 1 1 2 1 3 2 1 10
3 exp. 1,000 3 3 1 2 0 2 0 1 2
Total 12 2 16





Hematological AEs, n Gastrointestinal and 
hepatic AEs, n




G3 G4 G3 G4 G3 G4
1 600 3 2 0 1 0 0 0 0 0
2 800 3 1 0 1 0 0 0 0 4
3 1,000 3 3 1 4 2 3 2 1 10
3 exp. 1,000 3 8 1 2 0 2 0 1 2
Total 12 2 16
AE, adverse event; DLT, dose limiting toxicity; SAE, serious adverse event.
Table 4. Surgical complications after pump implantation
Patient Complication(s) Clavien-Dindo 
classification
CCI
1 Anaphylaxis II 20.9
2 Seroma I 8.7
3 Seroma











5 Seroma I 8.7
6 – – 0
7 Cholangitis II 20.9
8 Seroma I 8.7
9 – – 0
10 Seroma I 8.7






CCI, Comprehensive Complication Index.
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Pump- and Catheter-Related Complications
A total of 83.3% of the patients presented with mild 
complications after initial surgery (Clavien-Dindo I–
IIIa) up to discharge, with a median CCI of 12.2 (Ta-
ble 4). Major pump- or catheter-related complications 
occurred only in 2 patients (16.7%). In both cases these 
were classified as Clavien-Dindo IIIb complications, as 
they required a surgical reintervention. One patient de-
veloped a volvulus of the colon 8 months after pump 
implantation, due to strangulation of the pump cathe-
ter, requiring surgery and stop of the treatment. The 
other patient had a dysfunction of the pump catheter 
system due to a broken metal insertion at the pump con-
tainer that occurred 3 months after treatment. The 
pump had to be removed. The median time from pump 
placement to the start of chemotherapy was 10 days 
(range 4–27).
Response Assessment and Resection Rate after 3 Months
Response assessment according to RECIST 1.1 was 
performed after 3 months of treatment with CT/PET-CT 
scans. In total, a complete response, partial response, and 
stable disease was achieved in 0, 3 (27%), and 8 (73%) pa-
tients, respectively (Fig. 2). None of the patients had pro-
gressive disease at that time. One patient was excluded 
from the analysis (not applicable) due to early death after 
6 weeks due to a pulmonary embolism. Only patients with 
intrahepatic CCA showed a partial response according to 
RECIST 1.1. Both patients with hilar CCA had no objec-
tive response of the tumor. The time to best response was 
4.6 months (range 2–26).
None of the patients was resectable after 3 months of 


































■ GEM 600 mg/m2
■ GEM 800 mg/m2
■ GEM 1,000 mg/m2
Fig. 2. Response assessment according to 
RECIST 1.1 after 3 months of treatment. *, 
patients with hilar cholangiocarcinoma; +, 
patient with gallbladder and liver paren-
chyma infiltration; GEM, gemcitabine.
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Fig. 3. Median progression-free survival (mPFS; a) and median 
overall survival (mOS; b) curves with unresectable cholangiocar-
cinoma. PFS was defined as the time from start of chemotherapy 
until disease progression or death from any cause. OS was defined 
as the time from start of chemotherapy until death from any cause. 
Vertical lines indicate that patients’ data were censored.





Median follow-up from start of treatment was 43.8 
months (range 27–69). Patients alive at the time of evalu-
ation were censored at the date of last follow-up (data log 
April 30, 2018). No patients were lost to follow-up. The 
1-, 2-, and 3-year OS rate was 75, 42, 33%, respectively. 
Median OS was 23.9 months (range 1–49). The 1-, 2-, and 
3-year PFS rate was 42, 8, and 8%, respectively. Median 
PFS was 10.1 months (range 2–40) (Fig. 3). Of the 8 pa-
tients with progressive disease, 4 had intra- and extrahe-
patic progression, 2 had extrahepatic progression only, 
and 2 had intrahepatic progression only.
Post-Study Treatment
After completion of the 3 months of study treatment, 
8 patients (66.7%) continued with gemcitabine/cisplatin 
for a median of 7.5 cycles in total (range 6–11), every 3 
weeks, and HAI-FUDR for a median time of 5.5 months 
(range 4–26). Treatment was stopped due to disease pro-
gression (n = 3), pump complications that required a 
pump explantation (volvulus: n = 1; pump dysfunction: 
n = 1), and other reasons (n = 3).
One patient had a tumor resection following 6 cycles 
of gemcitabine/cisplatin and HAI-FUDR, but achieving 
only R1 resection status with eventual tumor progression 
1 year postoperatively. Another patient – after further 
second-line chemotherapy with irinotecan and HAI- 
FUDR/mitomycin C and later radioembolization treat-
ment – received a living donor liver transplant following 
hepatectomy and has remained in complete remission for 
24 months until data cut-off. The patient who had the 
volvulus has remained progression free without treat-
ment for 42 months until data cut-off.
Discussion
This study demonstrated the feasibility of the combi-
nation treatment of systemic gemcitabine/cisplatin with 
HAI-FUDR in patients with unresectable CCA with an 
acceptable toxicity profile. The treatment-related toxicity 
was comparable to that reported in previous studies with 
HAI treatment and systemic treatment for CCA. The 
most frequently seen higher-grade AEs were an increase 
in liver function test results, the occurrence of predomi-
nantly hepatobiliary infections, cytopenias due to the sys-
temic treatment, and fatigue. The toxicities due to the 
study medication were well manageable with appropriate 
supportive measures as well as with a dose delay or reduc-
tion of the study medication.
The MTD for gemcitabine was defined as 800 mg/m2, 
which is 20% lower than usually administered in combi-
nation with cisplatin. We considered this reduction of 
one systemically administered drug acceptable, as our pa-
tients had no extrahepatic disease and the addition of 
HAI-FUDR to the doublet intensified the exposure of the 
liver tumors to cytotoxic agents compared to the fully 
dosed systemic doublet alone. Accordingly, we observed 
some considerable responses and long-term tumor con-
trol but also extrahepatic relapses irrespective of the ad-
ministered gemcitabine dose, highlighting the impor-
tance of FUDR in this treatment strategy.
The partial response rate was 27%, and the disease 
control rate 100%. No patients experienced tumor pro-
gression within the 3 months. This finding compares fa-
vorably with the reported tumor control rates of about 
80% with cisplatin and gemcitabine alone [5].
We also observed that only patients with intrahepatic 
CCA, but not those with hilar CCA, achieved significant 
responses to the study treatment. One obvious reason is 
the rather longitudinal growth of hilar CCA along the bile 
ducts and the difficulty to assess response based on mor-
phological RECIST criteria compared to intrahepatic 
CCA. However, this finding could in part also be ex-
plained by the fact that the tumor biology of hilar bile duct 
carcinomas is different from that of carcinomas arising 
from the intrahepatic bile ducts, and may respond less to 
HAI and systemic treatment. Also, HAI chemotherapy is 
given via the hepatic artery and may thus cause toxic bil-
iary sclerosis, as has been described in earlier studies [20, 
21]. We hypothesize that this toxic effect, which can be 
reduced by the additional administration of steroids, may 
render the affected bile ducts more prone to infectious 
complications than they already are due to the stenosing 
growth of the tumor, resulting in delay, reduction, or 
omission of effective treatment [20–22].
Although none of the patients achieved resectability 
after 3 months, the 3-year OS rate was quite promising 
with 33%. The median OS and PFS was 23.9 and 10.1 
months, respectively. In 2 patients, long-term remission 
could be achieved, with disease stabilization in one pa-
tient as of data cut-off, while the other patient underwent 
successful liver transplantation after disease control for 
over 2 years. This outcome is quite pleasing, since all pa-
tients included had locally advanced and not primarily 
resectable disease, and one-third of the patients had lo-
coregional nodal involvement. This finding is in line with 
large multi-institutional series showing nodal involve-
ment in up to 37% of cases [23, 24]. According to most 
experts, patients with locoregional nodal involvement 
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may still be candidates for surgery, but should be ap-
proached with caution, considering chemotherapy first 
[25]. The survival we observed was in line with retrospec-
tive data on intra-arterial HAI-FUDR in CCA patients 
reported so far [6, 8]. It has to be stated, however, that the 
prognosis may generally be more favorable in our study 
patients than in the patients included in the ABC-02 
study, as our patients had no distant metastatic disease at 
diagnosis [26].
To date, no study has been published to our knowledge 
that has investigated the combination treatment of sys-
temic chemotherapy with gemcitabine and cisplatin, 
which may be considered the current standard of prac-
tice, and intrahepatic chemotherapy with FUDR in pa-
tients with nonresectable CCA in a prospective fashion. 
Our results strengthen the notion that combining the cur-
rent standard treatment with an efficacious third drug – 
the latter given intra-arterially to avoid additional sys-
temic toxicities – is feasible and may achieve promising 
results in selected patients, although downsizing to 
achieve resectability seems still challenging in this diffi-
cult-to-treat disease. We used a surgically implantable 
pump system to administer the intrahepatic agent, but 
also more conventional port systems, implanted by inter-
ventional radiologists and thus more broadly available 
and more convenient for the patients, could be used for 
this purpose [27].
Conclusion
Intravenous gemcitabine/cisplatin plus HAI-FUDR is 
feasible and appears effective for disease control in unre-
sectable intrahepatic CCA. Our study may serve as the 
clinical basis for larger prospective studies evaluating this 
triplet combination.
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